Navigation Links
Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases
Date:2/4/2008

Survival advantage found in 'off-label' uses, report suggests

MONDAY, Feb. 4 (HealthDay News) -- Drug-coated stents are better than the bare-metal kind for treating complex arterial blockages, new research finds.

"There are two messages I would take away from the study," said Dr. Robert J. Applegate, a professor of cardiology at Wake Forest University and lead author of a report in the Feb. 12 issue of the Journal of the American College of Cardiology. "The first is that drug-eluting stents are very effective. They were effective in the kind of patients in the initial trials, with simpler problems. Then their effectiveness was broadened to all patients who underwent stent treatment, even in off-label use. All the benefits present in the early trials are showing in the patients that have these high-risk features."

High-risk factors include diabetes, kidney failure, a recent heart attack and longer blockages, Applegate said. "All of these have been matters of concern about the use of drug-eluting stents. We saw them to be effective in these patients."

The study compared results of 1,285 people with such complications who got drug-coated stents, flexible tubes implanted to keep blood vessels open after the clot-removing procedure called angioplasty and 1,164 people who had bare-metal stents. After two years, the incidence of nonfatal heart attacks or deaths was 29 percent lower for those getting drug-coated stents.

The drug-coated stents were also safer, with the incidence of stent-caused clotting roughly half that seen in the bare-metal stent recipients.

Another study reported in the same issue of the journal was more cautious about the long-term effectiveness of drug-coated stents. The study of 310 people who got stents after heart attacks found that those who got drug-coated stents were better off after a year than those getting bare-metal stents, but that there were worrying indications of a possible higher risk of artery reblockage in the coated-stent group.

Stents have been very much in the news lately, with studies such as one that found equal effectiveness of the two drug-coated stents now available in the American market, one sold by Boston Scientific, the other by Cordis.

That study was funded by the two companies, as was the newly reported Wake Forest study. Applegate said that financing of the study by industry did not affect the results of the research. "They had absolutely no influence on the study design, the acquisition of data, the interpretation of data or the scripting of the manuscript," he said.

Its getting harder to do meaningful medical research in the United States for a variety of reasons, said an accompanying editorial by Dr. Cindy Grines, vice chief of academic affairs at William Beaumont Hospital in Royal Oak, Mich. The somewhat frightening "off-label" designation, which means the U.S. Food and Drug Administration hasn't approved that use, is necessary because of the difficulty of conducting trials in the United States, she explained.

"Eighty percent of the studies now are being done outside the United States," Grines said.

Some of the blame goes to the complex rules imposed by the FDA, she said, but the propensity for people claiming damage to file suits also has a constraining effect.

"There are Web sites with legal advice," Grines said. "So, it is very defensive medicine that people are practicing. A consent form might be 10 pages long to do a simple study, which becomes financially undoable in most institutions. It would be really nice if we could have more ability to do these studies here."

More information

You can learn why and how stents are used from the American Heart Association.



SOURCES: Robert J. Applegate, M.D., professor, cardiology, Wake Forest University, Winston-Salem, N.C.; Cindy Grines, M.D., vice chief, academic affairs, William Beaumont Hospital, Royal Oak, Mich.; Feb. 12, 2008, Journal of the American College of Cardiology


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones
2. Study Finds Benefits With Drug-Coated Stents
3. Drug-Coated Stents Go Head to Head
4. Study Finds Both Coated Stents Perform the Same
5. Stents Slightly Better Than Bypass for Blocked Left Coronary Artery
6. Study examines self-expanding plastic stents in the treatment of benign esophageal conditions
7. Surgery Better Than Stents for Multiple Blockages
8. Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
9. Study looks at off-label use of biliary stents
10. Top10 research advances include studies on genetics and stem cell research, stents
11. Aeon Bioscience Continues Development of Drug Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases
(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the ... series, and attorneys from the firm’s global Life Sciences & Medical Technology Group have ...
(Date:12/8/2016)... Somerset, N.J. (PRWEB) , ... December 08, 2016 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... The PSCI was set up in 2006 as a non-profit organization to unite ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... as possible. With this in mind, SIGVARIS has created a new line of ... during bed rest and provide the benefits of graduated compression when transitioning from ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Valeant Pharmaceuticals International, Inc. (NYSE: ... positive results from a Phase 3, multicenter double-blind, ... and efficacy of IDP-118 (halobetasol propionate and tazarotene) ... Within the Phase 3 study of ... IDP-118 showed statistical significance to vehicle with a ...
(Date:12/8/2016)... Information products and services provider Elsevier has launched ... largest abstract and citation database of peer-reviewed literature, providing the scholarly ... publishers. The new set of metrics will improve decisions on where ... a journal,s editorial strategy. ... , CiteScore metrics comprise a ...
(Date:12/8/2016)... 2016 Dignitana, a world leader in medical ... Technology, creator of the award-winning, patented Boa® system, to ... the DigniCap® scalp cooling system. DigniCap® was cleared by ... and is the first medical scalp cooling device to ... system features a patented tight-fitting silicone cooling cap that ...
Breaking Medicine Technology: